Landscape Capital Management L.L.C. Purchases 155,048 Shares of Elanco Animal Health Incorporated $ELAN

Landscape Capital Management L.L.C. lifted its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 106.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 300,930 shares of the company’s stock after purchasing an additional 155,048 shares during the quarter. Landscape Capital Management L.L.C. owned 0.06% of Elanco Animal Health worth $6,061,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of ELAN. UBS Group AG lifted its position in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after buying an additional 5,961,457 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares during the last quarter. Bowen Hanes & Co. Inc. purchased a new position in shares of Elanco Animal Health during the third quarter worth approximately $47,626,000. Dimensional Fund Advisors LP raised its stake in shares of Elanco Animal Health by 8.6% during the third quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock worth $497,610,000 after acquiring an additional 1,962,276 shares in the last quarter. Finally, Jupiter Asset Management Ltd. lifted its holdings in shares of Elanco Animal Health by 98.8% in the 3rd quarter. Jupiter Asset Management Ltd. now owns 3,716,849 shares of the company’s stock worth $74,857,000 after acquiring an additional 1,846,907 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Trading Up 0.5%

Elanco Animal Health stock traded up $0.11 during mid-day trading on Friday, reaching $22.79. 240,483 shares of the company traded hands, compared to its average volume of 4,483,958. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $27.72. The firm has a market capitalization of $11.33 billion, a price-to-earnings ratio of -47.48, a P/E/G ratio of 2.99 and a beta of 1.83. The firm’s 50 day moving average price is $24.51 and its 200 day moving average price is $22.15.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the previous year, the firm posted $0.14 EPS. The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on ELAN. Leerink Partners upped their price target on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Wednesday, November 19th. Morgan Stanley boosted their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. Finally, Barclays began coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.67.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.